Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis
- 29 July 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Applied Health Economics and Health Policy
- Vol. 15 (6), 805-816
- https://doi.org/10.1007/s40258-017-0341-y
Abstract
Background Skin cancer exerts a large and growing burden on health systems. With new pharmacotherapies for metastatic melanoma now available, a contemporary understanding of the cost burden of melanoma control is warranted. Objective To comprehensively assess the healthcare costs of malignant melanoma diagnosis and treatment in Australia, over 3 years after diagnosis. Methods We developed a decision-analytic model and micro-costing method to estimate the mean cost per patient for melanoma, incorporating all diagnostic and treatment modalities used in Australia (2017 AU$). By using the de-identified 10% sample of Medicare Benefits Scheme, we analysed health service use and supplemented our analyses with published estimates. We took a health system cost perspective, and addressed input uncertainty with sensitivity analyses. Results The mean annual cost per patient for melanoma stage 0/I/II was AU$1681 (US$1175) rising to AU$37,729 (US$26,365) for stage III resectable, and AU$115,109 (US$80,440) for stage III unresectable/IV. Three-year costs for stage III unresectable/IV were AU$187,720. Nationally, the annual estimated cost for treatment of all new cases of in situ and invasive melanomas was AU$201 million (95% CI: AU$187 to AU$216 million). When we included treatments for presumptive melanoma later found to be benign lesions, the estimated annual cost burden reached AU$272 million. Conclusion With rapidly rising treatment costs, there is a need to consider a comprehensive melanoma control strategy that includes primary prevention of skin cancers and cost-effective sun protection initiatives.Funding Information
- National Health and Medical Research Council of Australia (552429)
- National Health and Medical Research Council (APP1058522, 1073898, APP1001456)
This publication has 35 references indexed in Scilit:
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III TrialJournal of Clinical Oncology, 2015
- Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screeningEuropean Journal Of Cancer Prevention, 2015
- Measuring current and future cost of skin cancer in EnglandJournal of Public Health, 2013
- Is sentinel node biopsy the standard of care in melanoma management? The opinions and practices of Australian specialistsAustralasian Journal of Dermatology, 2012
- Accuracy in skin cancer diagnosis: A retrospective study of an Australian public hospital dermatology departmentAustralasian Journal of Dermatology, 2012
- Managing patients with cutaneous squamous cell carcinoma metastatic to the axilla or groin lymph nodesAustralasian Journal of Dermatology, 2010
- Estimativa do custo do tratamento de câncer de pele tipo melanoma no Estado de São Paulo - BrasilAnais Brasileiros de Dermatologia, 2009
- Societal Cost of Skin Cancer in Sweden in 2005Acta Dermato Venereologica, 2008
- Diagnosis and management costs of suspicious skin lesions from a population-based melanoma screening programmeJournal of Medical Screening, 2007
- Surgery and Adjuvant Radiotherapy in Patients with Cutaneous Head and Neck Squamous Cell Carcinoma Metastatic to Lymph Nodes: Combined Treatment Should be Considered Best PracticeThe Laryngoscope, 2005